ArticleCancer research2023
Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.
Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- A benchmark study of vision and pathology foundation models for computational pathology.Nature communications · 2026Article
- A novel model for assessing lymph node metastasis and the immune microenvironment in breast cancer by integrating digital pathology images and transcriptomics.Discover oncology · 2026Article
- Multi-Scale Mapping of Gene Expression from Whole-slide Images for Identifying Phenotype-Associated Subpopulations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decoding immunotherapy response through computational modeling.Nature communications · 2026Review
- Multifocal cohort analysis unveils cell types associated with regional lymph node seeding in prostate cancer.Genome medicine · 2026Article
- AI-driven precision diagnosis and treatment of prostate cancer: a narrative review.Frontiers in oncology · 2026Review
- The state of the art in artificial intelligence and digital pathology in prostate cancer.Nature reviews. Urology · 2026Review
- A novel deep learning radiopathomics model for predicting carcinogenesis promotor cyclooxygenase-2 expression in common bile duct in children with pancreaticobiliary maljunction: a multicenter study.Insights into imaging · 2025Article
- AI in Histopathology Explorer for comprehensive analysis of the evolving AI landscape in histopathology.NPJ digital medicine · 2025Article
- Fractal dimensions for tumour-related cell types of prostate cancer on histopathology images using multiple-threshold box counting algorithm.Biophysics and physicobiology · 2025Article
- Digital profiling of gene expression from histology images with linearized attention.Nature communications · 2024Article
- Towards Digital Quantification of Ploidy from Pan-Cancer Digital Pathology Slides using Deep Learning.bioRxiv : the preprint server for biology · 2024Article
- Digital profiling of cancer transcriptomes from histology images with grouped vision attention.bioRxiv : the preprint server for biology · 2024Article
- Artificial intelligence model predicts M2 macrophage levels and HCC prognosis with only globally labeled pathological images.Frontiers in oncology · 2024Article
- Machine learning approaches for spatial omics data analysis in digital pathology: tools and applications in genitourinary oncology.Frontiers in oncology · 2024Review
- TP53 gene implications in prostate cancer evolution: potential role in tumor classification.Medicine and pharmacy reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profiling in a clinical setting is complicated by tumor heterogeneity. Deep learning models that predict the spatial presence of TP53 mutations in whole slide images (WSI) offer the potential to mitigate this issue. To assess the potential of WSIs as proxies for spatially resolved profiling and as biomarkers for aggressive disease, we developed TiDo, a deep learning model that achieves state-of-the-art performance in predicting TP53 mutations from WSIs of primary prostate tumors. In an independent multifocal cohort, the model showed successful generalization at both the patient and lesion level. Analysis of model predictions revealed that false positive (FP) predictions could at least partially be explained by TP53 deletions, suggesting that some FP carry an alteration that leads to the same histological phenotype as TP53 mutations. Comparative expression and histologic cell type analyses identified a TP53-like cellular phenotype triggered by expression of pathways affecting stromal composition. Together, these findings indicate that WSI-based models might not be able to perfectly predict the spatial presence of individual TP53 mutations but they have the potential to elucidate the prognosis of a tumor by depicting a downstream phenotype associated with aggressive disease biomarkers. SIGNIFICANCE: Deep learning models predicting TP53 mutations from whole slide images of prostate cancer capture histologic phenotypes associated with stromal composition, lymph node metastasis, and biochemical recurrence, indicating their potential as in silico prognostic biomarkers. See related commentary by Bordeleau, p. 2809.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.